# Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD

> **NCT03744806** · — · COMPLETED · sponsor: **Medical University of Lublin** · enrollment: 48 (actual)

## Conditions studied

- Exudative Age-related Macular Degeneration

## Interventions

- **DRUG:** Bevacizumab Injection

## Key facts

- **NCT ID:** NCT03744806
- **Lead sponsor:** Medical University of Lublin
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-09
- **Final completion:** 2018-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03744806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03744806, "Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03744806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*